A Nordic multicenter study by Glintborg et al. comparing secukinumab with TNF inhibitors revealed doubled hospitalization rates for infections with secukinumab (IR 5.0 vs. 2.3/100 patient-years for adalimumab), though attenuated after confounding adjustment, advocating personalized infection risk stratification (99). This evidence concerns the gene TNF and infection.